Biochemistry

    

Ad26.cov2.s Vaccine Safety and Effectivity Profile

Authors: Paz Azakarian, Mino Hazit

Janssen’s SARS-CoV-2 vaccine “Ad26.CoV2.S” reported 66.9% efficacy in the trial [1]. The safety and efficacy report contains certain statistics that do not hold any value without further elaboration. The protocols set to define COVID severities do not capture enough data to validify efficacy of preventive-type medicine. Self reported side effects also suggest the safety profile needs reevaluation.

Comments: 8 Pages.

Download: PDF

Submission history

[v1] 2021-10-26 18:55:12
[v2] 2021-11-04 00:38:41

Unique-IP document downloads: 356 times

Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus